Analyst predicts growth for Baxter's blood product

01/15/2010 | Los Angeles Times (tiered subscription model)

A Morgan Keegan analyst projected that 2010 sales of Baxter International's intravenous immunoglobulin will exceed Wall Street expectations. Demand for the blood product, used to treat immune disorders and infections, is expected to increase 5% to 8% annually in the next few years, and as much as 10% if the economy improves, the analyst said.

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT